174 related articles for article (PubMed ID: 21945552)
1. A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer.
Adams SF; Marsh EB; Elmasri W; Halberstadt S; Vandecker S; Sammel MD; Bradbury AR; Daly M; Karlan B; Rubin SC
Gynecol Oncol; 2011 Dec; 123(3):486-91. PubMed ID: 21945552
[TBL] [Abstract][Full Text] [Related]
2. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin.
Safra T; Borgato L; Nicoletto MO; Rolnitzky L; Pelles-Avraham S; Geva R; Donach ME; Curtin J; Novetsky A; Grenader T; Lai WC; Gabizon A; Boyd L; Muggia F
Mol Cancer Ther; 2011 Oct; 10(10):2000-7. PubMed ID: 21835933
[TBL] [Abstract][Full Text] [Related]
3. Is it equivalent? Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment.
Smith JA; Costales AB; Jaffari M; Urbauer DL; Frumovitz M; Kutac CK; Tran H; Coleman RL
J Oncol Pharm Pract; 2016 Aug; 22(4):599-604. PubMed ID: 26183293
[TBL] [Abstract][Full Text] [Related]
4. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
5. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
Bookman MA; Tyczynski JE; Espirito JL; Wilson TW; Fernandes AW
Gynecol Oncol; 2017 Jul; 146(1):58-63. PubMed ID: 28454659
[TBL] [Abstract][Full Text] [Related]
6. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
[TBL] [Abstract][Full Text] [Related]
7. Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinum-refractory/resistant epithelial ovarian cancer.
Nomura H; Tsuda H; Kataoka F; Chiyoda T; Yamagami W; Tominaga E; Susumu N; Aoki D
Eur J Gynaecol Oncol; 2012; 33(1):86-9. PubMed ID: 22439412
[TBL] [Abstract][Full Text] [Related]
8. Liposome-encapsulated doxorubicin citrate (Myocet) for treatment of recurrent epithelial ovarian cancer: a retrospective analysis.
Eitan R; Fishman A; Meirovitz M; Goldenberg H; Amit A; Koren C; Schneider Y; Rosengarten O; Neuman A; Keren-Rosenberg S; Safra T
Anticancer Drugs; 2014 Jan; 25(1):101-5. PubMed ID: 24263191
[TBL] [Abstract][Full Text] [Related]
9. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
[TBL] [Abstract][Full Text] [Related]
10. Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations.
Hollis RL; Meynert AM; Churchman M; Rye T; Mackean M; Nussey F; Arends MJ; Sims AH; Semple CA; Herrington CS; Gourley C
BMC Cancer; 2018 Jan; 18(1):16. PubMed ID: 29298688
[TBL] [Abstract][Full Text] [Related]
11. Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.
Helpman L; Zidan O; Friedman E; Kalfon S; Perri T; Ben-Baruch G; Korach J
J Gynecol Oncol; 2017 Sep; 28(5):e61. PubMed ID: 28657222
[TBL] [Abstract][Full Text] [Related]
12. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status.
Kotsopoulos J; Rosen B; Fan I; Moody J; McLaughlin JR; Risch H; May T; Sun P; Narod SA
Gynecol Oncol; 2016 Jan; 140(1):42-7. PubMed ID: 26556769
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
Monk BJ; Herzog TJ; Kaye SB; Krasner CN; Vermorken JB; Muggia FM; Pujade-Lauraine E; Park YC; Parekh TV; Poveda AM
Eur J Cancer; 2012 Oct; 48(15):2361-8. PubMed ID: 22541893
[TBL] [Abstract][Full Text] [Related]
14. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.
Kim KH; Jelovac D; Armstrong DK; Schwartz B; Weil SC; Schweizer C; Alvarez RD
Gynecol Oncol; 2016 Feb; 140(2):210-4. PubMed ID: 26644263
[TBL] [Abstract][Full Text] [Related]
15. BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
Harter P; Johnson T; Berton-Rigaud D; Park SY; Friedlander M; Del Campo JM; Shimada M; Forget F; Mirza MR; Colombo N; Zamagni C; Chan JK; Imhof M; Herzog TJ; O'Donnell D; Heitz F; King K; Stinnett S; Barrett C; Jobanputra M; Xu CF; du Bois A
Gynecol Oncol; 2016 Mar; 140(3):443-9. PubMed ID: 26740259
[TBL] [Abstract][Full Text] [Related]
16. TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer.
Erriquez J; Becco P; Olivero M; Ponzone R; Maggiorotto F; Ferrero A; Scalzo MS; Canuto EM; Sapino A; Verdun di Cantogno L; Bruna P; Aglietta M; Di Renzo MF; Valabrega G
Gynecol Oncol; 2015 Sep; 138(3):627-33. PubMed ID: 26100858
[TBL] [Abstract][Full Text] [Related]
17. The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer.
Safra T; Rogowski O; Muggia FM
Int J Gynecol Cancer; 2014 Mar; 24(3):488-95. PubMed ID: 24457564
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer.
Mayer C; Brucker J; Schuetz F; Domschke C; Bechstein S; Heil J; Golatta M; Wallwiener M; Sohn C; Schneeweiss A; Rom J
Arch Gynecol Obstet; 2016 Jul; 294(1):123-9. PubMed ID: 26498757
[TBL] [Abstract][Full Text] [Related]
19. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
[TBL] [Abstract][Full Text] [Related]
20. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
Kaye SB; Lubinski J; Matulonis U; Ang JE; Gourley C; Karlan BY; Amnon A; Bell-McGuinn KM; Chen LM; Friedlander M; Safra T; Vergote I; Wickens M; Lowe ES; Carmichael J; Kaufman B
J Clin Oncol; 2012 Feb; 30(4):372-9. PubMed ID: 22203755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]